Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours

Article ID	Journal	Published Year	Pages	File Type
8536966	Pharmacology & Therapeutics	2018	27 Pages	PDF

Abstract

We propose a comprehensive two-part review providing a panoramic approach of the successes and failures of targeted agents in GI cancers to unravel the pharmacologic opportunities and future directions for these agents in GI oncology. In this second part, we will focus on NET, HCC, and GIST, whose treatment relies primarily on targeted therapies.

Keywords

EGFR DTPA EGF IGF mAb PD-1 ORR PD-L1 RFS SDH mTOR TCr DOPA SDF HSP90 FGF SST MDS VIP BSC TTF DFS CML hpf QOL TGF GM-CSF TTR SSTR PDGF Treg TACE PNET HGF DCR TKR PlGF Folfox VEGFR 5FU BCLC PDGFR TTP granulocyte-macrophage colony stimulating factor Ang2 PRRT MKI TSC2 Antiangiogenics SSTA AML NAFLD CTLA-4 vasointestinal peptide Quality of life natural killer 95%CI transarterial chemoembolization HCC MAPK PFs Adenosine Triphosphate ATP alpha fetoprotein amino acid somatostatin analogue Monoclonal antibody cytotoxic T lymphocyte antigen-4 angiopoietin 2 MRI interferon IFN interleukin progression-free survival Recurrence-free survival Disease free survival overall survival Best supportive care non-alcoholic fatty liver disease transforming growth factor AFP Magnetic resonance imaging neuroendocrine tumour Pancreatic neuroendocrine tumour RECIST NET Gastrointestinal Time to progression Time to failure time to recurrence World Health Organization myelodysplastic syndrome Somatostatin succinate dehydrogenase CT-scan Stromal cell-derived factor epidermal growth factor placental growth factor Hepatocyte growth factor 95% confidence interval Vascular endothelial growth factor Vascular Endothelial Growth Factor (VEGF)platelet-derived growth factor fibroblast growth factor Insulin-like growth factor phosphatase and tensin homolog 5-fluorouracil Chronic myeloid leukemia Programmed death ligand 1 Programmed death 1 Gist response evaluation criteria in solid tumours Resistance multikinase inhibitor mTOR inhibitors high-power field overall response rate Disease control rate hazard ratio wild type mammalian target of rapamycin Growth hormone HBV HCV Hepatitis C virus Performance status hepatitis B virus PET Heat shock protein 90 mitogen-activated protein kinase tuberous sclerosis complex 2 Pten Hepatocellular carcinoma WHO Kit Tyrosine kinase receptor Somatostatin receptor platelet-derived growth factor receptor vascular endothelial growth factor receptor Epidermal growth factor receptor T-cell receptor